NEWS

  • ISEV-ELBS Intersociety Working Group

    We are pleased to announce that we have founded an Intersociety Working Group together with ISEV.

    This working group aims to support the clinical translation of EV-related biomarker research.


    HISTORY
    The ISEV-ELBS Intersociety Working Group was founded in 2023. ELBS is the European Liquid Biopsy Society, and this working group aims to improve the quality of biobanks used for clinical biomarker exploration, which includes EV-related biomarker research. In the last 20 years, there has been a revolution in early diagnosis, prognosis and therapeutic efficacy of diseases based on information collected from non-invasive liquid biopsies.

    VISION AND AIMS
    Together the ISEV-ELBS Intersociety Working Group aims to foster collaboration between the two societies with the goal of promoting reproducibility of liquid biopsy-EV preparation and analysis and encouraging discussion on EV research and its applications in liquid biopsy approaches. Together the two societies will co-host meetings, develop collaborative initiatives and report developments in the EV-liquid biopsy field. This will foster the development of novel EV biomarkers and their translation to the clinic.


    MEET THE CHAIR

    Caterina Nardella     Senior Scientist and Programme Manager, Laboratory of Computational and Functional Oncology
    Department of Cellular, Computational and Integrative Biology (CIBIO)
    University of Trento, Italy
    caterina.nardella@unitn.it

    An Hendrix     Full professor, Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium
    Principal investigator, Cancer Research Institute Ghent, Ghent, Belgium Founder and President of the Belgian Society for Extracellular Vesicles
    an.hendrix@ugent.be

    Carlos Salomon Gallo
    Professor
    Director, UQ Centre for Extracellular Vesicle Nanomedicine
    UQ Centre for Clinical Research
    Faculty of Medicine
    The University of Queensland, Australia
    c.salomongallo@uq.edu.au

    Julia V. Burnier     Director, Liquid Biopsy Unit
    Research Institute of the McGill University Health Centre,Montréal, Canada
    julia.burnier@mcgill.ca



    NEWS:     work in progress

    OUTPUTS: work in progress

    EVENTS: work in progress

  • Logo UCIPredict
    Lupe zum Vergrößern des Bildes
    Team UCIPredict
    C. Jerónimo, M. Dueñas, G. Güllü Amuran, K. Lundberg

    Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors (UCIPredict)

    UCIPredict is an EU Transcan project coordinated by ELBS member Marta Dueñas (CIBER, Spain) together with multiple partner institutions across Europe. The project is intended to develop an innovative and reliable urine and blood-based biomarker test for response prediction to immunotherapy (IT) and tumour recurrence, using non-invasive techniques measuring circulating biomarkers from tumour and tumour microenvironment for urothelial cancer (UC). The main objective of this project is to identify molecular and cellular signatures from urine and blood samples to develop a robust and reproducible laboratory tool for personalized therapy and IT response prediction in UC patients. UCIPredict will provide a non-invasive innovative tool for patient prognosis and IT response in UC. Its implementation in clinical practice for IT response prediction would increase the rate of patients receiving the best clinical benefit.

    UCIPredict

    3 POSITIONS FOR THE PROJECT ‘PANCAID’ WITHIN THE FIELD OF LIQUID BIOPSY

    Dear ELBS members, the Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf (UKE) (chaired by Prof. Klaus Pantel) is hiring academic personnel for the newly granted EU-funded project ‘PANCAID’ within the field of liquid biopsy. The UKE project part will specifically involve the establishment and validation of ultra-sensitive blood tests for pancreatic cancer using a comprehensive panel of sensitive liquid biopsy markers including circulating cells, cell-free DNA, proteins and metabolites.

    OPEN POSITIONS:
    1x PhD student
    1x Postdoc
    1x Administrative Postdoc

    For further information and contact details please see the attached job offers.

    9 DOCTORAL CANDIDATE POSITIONS IN MSCA DOCTORAL NETWORK COLOMARK


    We are seeking 9 highly motivated fellows to pursue a career in science, obtain a PhD abroad and work in one of the three-year research projects we are offering under the doctoral Network Marie Skłodowska-Curie Action ColoMARK.

    ColoMARK integrates 17 teams with multidisciplinary expertise (omics,epidemiology, microbiome, circulating tumour DNA, bioinformatics, statistics & machine learning, assay development, circulating RNAs, circulating tumour cells, tumour profiling, clinics) aiming at the identification and development of novel colorectal cancer (CRC) biomarkers via state-of-the-art liquid biopsy approaches. ColoMARK will provide cross- and interdisciplinary innovative training with special emphasis on transversal competences to 10 doctoral candidates (DCs). They will constitute a next generation of effective, multi-skilled and proactive future professionals that comply with the tenets of the Principles for Innovative Doctoral Training, and that achieve enhanced intersectoral employability.

    Detailed information on the individual projects, and application procedure can be found in the below document or https://euraxess.ec.europa.eu/jobs/53134

  • On Friday October 28th 2022, the ELBS invites its members to attend in the annual general assembly (GA) of our network. This year, the ELBS GA is kindly co-hosted by our member Dr. Catherine Alix-Panabières at the Novel Faculty of Medicine in Montpellier, France.

    The GA will be a full day hybrid event providing detailed insights into the activities and plans of the network across its various working groups, the introduction of new members, collaborative project presentations, and ample time to network.

    We look forward to welcoming all members to the ELBS GA 2022!

    Kind regards,

    Prof. Dr. med. Klaus Pantel (ELBS Chair) and Dr. Claudia Koch (Project Management)